BB

BRAIN Biotech AG

Europe, Hessen, Germany, Zwingenberg

Description

BRAIN Biotech develops and produces enzymes, proteins, microbial production strains and bioactives for industrial applications

Investor Profile

BRAIN Biotech AG has backed more than 4 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 25% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series B, Undisclosed rounds (top funding stages).
  • Majority of deals are located in United Kingdom, Germany.
  • Strong thematic focus on Biotechnology, Health Care, Biopharma.

Stage Focus

  • Series A (25%)
  • Series B (25%)
  • Undisclosed (25%)
  • Seed (25%)

Country Focus

  • United Kingdom (75%)
  • Germany (25%)

Industry Focus

  • Biotechnology
  • Health Care
  • Biopharma
  • Medical
  • Chemical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does BRAIN Biotech AG frequently co-invest with?

Seneca Partners
Europe, St. Helens, United Kingdom, Haydock
Co-Investments: 2
Eva Pharma
Africa, Al Jizah, Egypt, Gîza
Co-Investments: 2
Bionova Capital
Europe, Lisboa, Portugal, Lisbon
Co-Investments: 1
Development Bank of Wales
Europe, Cardiff, United Kingdom, Cardiff
Co-Investments: 1
Wealth Club
Europe, Bristol, City of, United Kingdom, Bristol
Co-Investments: 1

Which angels does BRAIN Biotech AG often collaborate with?

FF
Europe, Auvergne, France, Mayet-de-montagne
Shared Deals: 1
JM
North America, Massachusetts, United States, Cambridge
Shared Deals: 2

What are some of recent deals done by BRAIN Biotech AG?

SolasCure

Cambridge, Cambridgeshire, United Kingdom

Transforming chronic wound care with breakthrough enzymatic technology

BiopharmaBiotechnologyHealth CareMedical
Series BMar 27, 2023
Amount Raised: $13,403,144
SolasCure

Cambridge, Cambridgeshire, United Kingdom

Transforming chronic wound care with breakthrough enzymatic technology

BiopharmaBiotechnologyHealth CareMedical
Series AAug 9, 2021
Amount Raised: $20,769,755
SolasCure

Cambridge, Cambridgeshire, United Kingdom

Transforming chronic wound care with breakthrough enzymatic technology

BiopharmaBiotechnologyHealth CareMedical
SeedAug 20, 2018
Enzymicals

Greifswald, Mecklenburg-Vorpommern, Germany

Enzymicals designs, develops, and implements chemo-biocatalytic routes to fine chemicals, APIs, and intermediates.

BiotechnologyChemicalHealth Care
UndisclosedJul 14, 2010